Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
14 May 2020GenericsRory O'Neill

Gilead agrees 127-country remdesivir licence with generic makers

Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Junshi licenses COVID-19 antibody tech from Lonza
14 July 2020   China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
Big Pharma
Gilead continues oncology expansion with Tizona deal
22 July 2020   Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Biotechnology
Junshi licenses COVID-19 antibody tech from Lonza
14 July 2020   China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
Big Pharma
Gilead continues oncology expansion with Tizona deal
22 July 2020   Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.

More on this story

Biotechnology
Junshi licenses COVID-19 antibody tech from Lonza
14 July 2020   China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
Big Pharma
Gilead continues oncology expansion with Tizona deal
22 July 2020   Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott